Early [¹⁸F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report. Pediatr Hematol Oncol 2010 Nov;27(8):650-7
Date
09/25/2010Pubmed ID
20863157Pubmed Central ID
PMC3083978DOI
10.3109/08880018.2010.504250Scopus ID
2-s2.0-77958051538 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.
Author List
Cole PD, McCarten KM, Drachtman RA, Alarcon Pd, Chen L, Trippett TM, Schwartz CLAuthor
Cindy L. Schwartz MD, MPH Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic Combined Chemotherapy ProtocolsDeoxycytidine
Fluorodeoxyglucose F18
Hodgkin Disease
Humans
Positron-Emission Tomography
Recurrence
Research Report
Retrospective Studies
Survival Analysis
Vinblastine
